Revised SPC: Xeljanz (tofacitinib) tablets
Myocardial infarction has been added as an uncommon adverse effect. SPC also notes that owing to increased risk of serious infections, myocardial infarction, and malignancies in patients >65 years, tofacitinib should only be used in these patients if no alternatives are available
Source:
electronic Medicines compendium
SPS commentary:
Pfizer issued a Direct Healthcare Professional Communication in July highlighting that in the A3921133 trial, patients with rheumatoid arthritis, age ≥50 years with ≥1 additional CV risk factor, an increased incidence of MI was seen with tofacitinib vs TNFIs. There was also an increased incidence of malignancies, particularly lung cancer and lymphoma.